Antiarrhythmic effects of (-)-epicatechin-3-gallate, a novel sodium channel agonist in cultured neonatal rat ventricular myocytes.
Antiarrhythmic effects of (-)-epicatechin-3-gallate, a novel sodium channel agonist in cultured neonatal rat ventricular myocytes.
复制标题
(-)-表儿茶素-3-没食子酸酯(一种新型钠通道激动剂)对培养的新生大鼠心室肌细胞的抗心律失常作用。
DOI:
10.1016/j.bcp.2012.10.003
复制
发表时间:
2013
影响因子:
5.8
通讯作者:
Lin,Cheng-I
中科院分区:
文献类型:
--
作者:
Wu,AdonisZhi-Yang;Loh,Shih-Hurng;Cheng,Tzu-Hurng;Lu,Hsin-Hsiang;Lin,Cheng-I
(−)-Epicatechin-3-gallate (ECG), a polyphenol extracted from green tea, has been proposed as an effective compound for improving cardiac contractility. However, the therapeutic potential of ECG on the treatment of arrhythmia remains unknown. We investigated the direct actions of ECG on the modulation of ion currents and cardiac cell excitability in the primary culture of neonatal rat ventricular myocyte (NRVM), which is considered a hypertrophic model for analysis of myocardial arrhythmias. By using the whole-cell patch-clamp configurations, we found ECG enhanced the slowly inactivating component of voltage-gated Na+currents (INa) in a concentration-dependent manner (0.1–100μM) with an EC50value of 3.8μM. ECG not only shifted the current–voltage relationship of peak INato the hyperpolarizing direction but also accelerated INarecovery kinetics. Working at a concentration level of INaenhancement, ECG has no notable effect on voltage-gated K+currents and L-type Ca2+currents. With culture time increment, the firing rate of spontaneous action potential (sAP) in NRVMs was gradually decreased until spontaneous early after-depolarization (EAD) was observed after about one week culture. ECG increased the firing rate of normal sAP about two-fold without waveform alteration. Interestingly, the bradycardia-dependent EAD could be significantly restored by ECG in fast firing rate to normal sAP waveform. The expression of dominant cardiac sodium channel subunit, Nav1.5, was consistently detected throughout the culture periods. Our results reveal how ECG, the novel INaagonist, may act as a promising candidate in clinical applications on cardiac arrhythmias.